配售代理已根据配售协议的条款及条件按配售价 104.27 港元/股向不少于六 名独立承配人成功配售合计 73,800,000 股 H 股。前述独立承配人均为独立于本 公司或附属公司的任何董事、监事、最高行政人员、主要股东或前述之联系人且 与彼等无关的投资者。 证券代码：603259 证券简称：药明康德 公告编号：临 2025-055 无锡药明康德新药开发股份有限公司 关于公司完成新增发行 H 股配售的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 无锡药明康德新药开发股份有限公司（以下简称"本公司"）已根据 2024 年年度股东大会审议通过的《关于给予董事会增发公司 A 股和/或 H 股股份一般 性授权的议案》项下股东大会对董事会增发股份的授权，于 2025 年 8 月 7 日完 成发行境外上市外资股（H 股）（以下简称"本次配售"）。除非另有说明，本 公告所涉词语简称的含义与《关于根据一般性授权配售新 H 股的公告》（公告 编号：临 2025-053）的定义一致。 本次配售根据本公司的一般性授权发行。本次配售前，除因 ...

无锡药明康德新药开发股份有限公司 关于公司完成新增发行 H 股配售的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 无锡药明康德新药开发股份有限公司（以下简称"本公司"）已根据 2024 年年度股东大会审议通过的《关于给予董事会增发公司 A 股和/或 H 股股份一般 性授权的议案》项下股东大会对董事会增发股份的授权，于 2025 年 8 月 7 日完 成发行境外上市外资股（H 股）（以下简称"本次配售"）。除非另有说明，本 公告所涉词语简称的含义与《关于根据一般性授权配售新 H 股的公告》（公告编 号：临 2025-053）的定义一致。 配售代理已根据配售协议的条款及条件按配售价 104.27 港元/股向不少于六 名独立承配人成功配售合计 73,800,000 股 H 股。前述独立承配人均为独立于本 公司或附属公司的任何董事、监事、最高行政人员、主要股东或前述之联系人且 与彼等无关的投资者。 本次配售的募集资金净额为 7,647,380,352.00 港元，将按以下方式投入使用： (a) 约 90%将用于全球布局和产能建 ...

8月7日，药明康德公告称，已完成发行境外上市外资股（H股）7380万股，募集资金净额约76.47亿港 元。其中，约90%将用于全球布局和产能建设，约10%将用于补充一般运营资金。本次配售前，公司并 未根据一般性授权发行任何H股，本次配售完成后，公司已运用约96.68%的目前可动用的一般性授权。 0:00 ...

Core Viewpoint - The A-share market has seen significant inflows of financing funds, with a total financing balance nearing historical highs, indicating a bullish sentiment among investors [2][19]. Financing Overview - As of the end of July, the total financing balance in the A-share market reached 19,710.27 billion yuan, approaching the historical high of 20 trillion yuan in 2015. The net buying amount for the year was 1,122.09 billion yuan, with July alone contributing 1,328.74 billion yuan [2][19]. - In July, 26 out of 27 sectors experienced net inflows of financing funds, with only the fossil energy sector seeing outflows [5][19]. Sector Analysis - The electronic equipment sector led with a net inflow of 167.4 billion yuan, bringing its financing balance to 2,483.04 billion yuan, the highest among all sectors. Other top sectors included pharmaceuticals (153.61 billion yuan), information technology (150.11 billion yuan), non-ferrous metals (136.11 billion yuan), and finance (134.09 billion yuan) [5][8]. - The top three sectors by financing balance as of the end of July were electronic equipment (2,483.04 billion yuan), information technology (2,031.21 billion yuan), and finance (1,997.27 billion yuan) [8]. Individual Stock Performance - In July, 42 stocks had net inflows exceeding 5 billion yuan, primarily in the information technology, finance, and pharmaceuticals sectors. Notable stocks included Xinjiyuan (34.43 billion yuan), Northern Rare Earth (24.26 billion yuan), and Shenghong Technology (20.61 billion yuan) [12][13]. - The stock with the highest financing balance was Dongfang Caifu, with a balance of 234.2 billion yuan, followed by China Ping An (219.45 billion yuan) and Kweichow Moutai (169.01 billion yuan) [16][17]. Market Outlook - Analysts suggest that a new round of market momentum could be on the horizon, with institutional investors optimistic about future performance. The overall sentiment remains bullish despite recent market fluctuations [19][21][22].

Group 1 - China's innovative drug industry has significantly improved its capabilities, with the number of innovative drug pipelines ranking second globally at 4,804 in 2024, just behind the United States at 5,268 [1][10] - The global pipeline of emerging therapies includes cutting-edge technologies such as gene therapy, cell therapy, RNA therapy, ADC, and bispecific/multispecific antibodies, with the U.S. holding over 40% of the global pipeline [1][12] - The number of innovative drugs approved in China has increased from 53 in 2019 to 85 in 2024, indicating a compound annual growth rate of approximately 10% [15] Group 2 - The aging population in China is projected to reach 310 million people aged 60 and above by 2024, accounting for 22% of the total population, leading to a rise in chronic diseases [3][26] - The chronic disease prevalence among younger populations is increasing due to lifestyle factors, resulting in higher long-term medication demands [29][31] - The Chinese innovative drug market has surpassed a trillion-dollar scale, growing from $132.5 billion in 2019 to an estimated $159.2 billion in 2024, with a global market share of around 15% [31][32] Group 3 - The internationalization of Chinese innovative drugs has seen explosive growth, with license-out transaction amounts increasing from $900 million in 2019 to $51.9 billion in 2024, reflecting a compound annual growth rate of 125% [2][45] - The number of overseas clinical trials conducted by Chinese pharmaceutical companies has risen from 98 in 2019 to 193 in 2022, indicating a compound annual growth rate of 25.3% [50] - The Chinese innovative drug industry is transitioning from a "follower" to a "parallel" player in the global pharmaceutical landscape, with increasing contributions to global medical innovation [52] Group 4 - Investment recommendations include companies such as Heng Rui Medicine, WuXi AppTec, and Enhua Pharmaceutical, which have strong pipelines and growth potential [4][59][66] - Heng Rui Medicine has established multiple R&D centers globally and has a robust pipeline with several innovative drugs approved for clinical trials [59] - WuXi AppTec is a leading platform for pharmaceutical and medical device R&D, with strong growth in its TIDES business line and a favorable industry outlook [61]

证券代码：603259 证券简称：药明康德 公告编号：临 2025-055 无锡药明康德新药开发股份有限公司 关于公司完成新增发行 H 股配售的公告 本次配售的募集资金净额为 7,647,380,352.00 港元，将按以下方式投入使用： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 无锡药明康德新药开发股份有限公司（以下简称"本公司"）已根据 2024 年年度股东大会审议通过的《关于给予董事会增发公司 A 股和/或 H 股股份一般 性授权的议案》项下股东大会对董事会增发股份的授权，于 2025 年 8 月 7 日完 成发行境外上市外资股（H 股）（以下简称"本次配售"）。除非另有说明，本 公告所涉词语简称的含义与《关于根据一般性授权配售新 H 股的公告》（公告 编号：临 2025-053）的定义一致。 | 股东 | 股份 | 本次配售完成前 | 本次配售完成后 | | --- | --- | --- | --- | | | 类别 | | | 1 | | | 股份数量 | 占本 公 司 已 | 股份数量 | 占本 公 司 已 ...

FF305 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 佔有關事件前的現有已發 | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 | 行股份（不包括庫存股 | 庫存股份數目 | | | | | | 目 | 份）數目百分比 (註3) | | | | | 於下列日期開始時的結存(註1) | 2025年8月6日 | | 2,485,141,055 | | 0 | 2,485,141,055 | | 1). 其他 (請註明) | | | % | | | | | 參見B部 | | | | | | | | 變動日期 | 2025年8月7日 | | | | | | | 於下列日期結束 ...

Core Viewpoint - Danuo Pharmaceutical (Suzhou) Co., Ltd. is seeking to go public on the Hong Kong Stock Exchange, highlighting its innovative drug development in the field of bacterial infections, particularly targeting Helicobacter pylori infections, despite facing significant financial challenges [2][3]. Company Overview - Founded in 2013, Danuo Pharmaceutical has completed seven rounds of financing, with a post-investment valuation of 2.013 billion RMB in its latest round [2]. - The company’s core product, Rifoternizole, is positioned to be the first new molecular entity approved for treating Helicobacter pylori infections globally [3][4]. Product Pipeline - Danuo has developed a differentiated pipeline consisting of seven innovative assets, including three core products: Rifoternizole (TNP-2198), Rifocquinone (TNP-2092) injection, and TNP-2092 oral formulation [3]. - Rifoternizole is the most advanced product, with plans to submit a new drug application to the National Medical Products Administration by August 2025 [3]. Financial Situation - The company reported a cumulative loss of 376 million RMB in 2023, with a net debt of 932 million RMB and cash reserves of only 146 million RMB as of March 2025 [6][8]. - Research and development expenses accounted for a significant portion of the losses, with 90.7%, 82%, and 65.3% of total R&D spending allocated to core product development during the reporting period [6]. Market Potential - The global market for antibacterial drugs is projected to grow from 45.5 billion USD in 2024 to 84.3 billion USD by 2035, indicating a robust industry outlook despite challenges in the Chinese market [9]. Shareholder and Supplier Dynamics - WuXi AppTec, a major shareholder, also serves as a key supplier, raising potential concerns regarding the independence and fairness of related transactions [9][11]. - The largest supplier, identified as Supplier B, accounted for 53.5% of total procurement in the first quarter of 2025, further emphasizing the intertwined relationship between Danuo and WuXi [11][12].

相关事件 药明康德(02359.HK)完成配售7380万股 药明康德(02359.HK)8月6日耗资2799.17万元回购29.81万股A股 格隆汇8月7日丨药明康德(02359.HK)公告，董事会欣然宣布已达成所有条件并于2025年8月7日完成配 售。配售代理已根据配售协议的条款及条件按每股配售股份配售价104.27港元向不少于六名独立承配人 成功配售合共7380万股配售股份。 ...

配售的募集资金净额为76.47亿港元，将按以下方式投入使用：约90%将用于加速推进全球布局和产能 建设;及约10%将用于一般公司用途。 智通财经APP讯，药明康德(02359)发布公告，董事会欣然宣布已达成所有条件并于2025年8月7日完成配 售。配售代理已根据配售协议的条款及条件按每股配售股份配售价104.27港元向不少于六名独立承配人 成功配售合共7380万股配售股份。经董事作出一切合理查询后所知、所悉及所信，承配人及其各自的最 终实益拥有人均为独立于本公司及本公司关连人士且与本公司及本公司关连人士概无关连的第三方。 ...